Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-385 in Healthy Volunteers
NCT03748212Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-385 in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
CKD-385
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03748212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748212.